CNA3103

CNA3103 is a first-in-class, autologous chimeric antigen receptor T cell (CAR-T) therapy developed to target leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a cancer stem cell marker highly expressed in advanced colorectal cancer and some other solid tumors. The therapy consists of a patient’s own T lymphocytes that are genetically modified to express a CAR specific for LGR5, enabling the immune system to selectively recognize and eliminate cancer stem cells. By targeting these cells, which are implicated in tumor initiation, growth, metastasis, and resistance to conventional therapies, CNA3103 aims to achieve durable tumor suppression and reduce relapse rates. Preclinical studies have shown complete tumor regression with no recurrence after treatment. The product incorporates the antigen-binding domain of BNC101—a humanized monoclonal antibody against LGR5 previously tested in metastatic colorectal cancer patients[1][2][4][5].

Other names

Autologous anti-LGR5 CAR-T cellsLGR5-targeted CAR-T cellsLGR-5-targeted CAR-T cellsLGR 5-targeted CAR-T cells